Drug intelligence / Profile preview

SITBL2-1

Development stage: Preclinical
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

SITBL2-1 is a small interfering RNA (siRNA) designed to specifically target and silence the TBL2 gene. Research indicates that knockdown of TBL2 by SITBL2-1 significantly inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of glioblastoma (GBM) cells, while promoting apoptosis. This therapeutic effect is mediated by the enhancement of autophagy through the AMPK/mTOR signaling pathway. These findings suggest that SITBL2-1, by modulating TBL2, could represent a potential therapeutic agent for glioblastoma.

Other names: TBL2 silencingTBL-2 silencingTBL 2 silencingknockdown of TBL2

Beyond the preview

Go deeper on SITBL2-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SITBL2-1.

Explore the full profile